Overview

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy

Status:
Withdrawn
Trial end date:
2026-05-13
Target enrollment:
Participant gender:
Summary
This study is for participants with Non-small Cell Lung Cancer that has spread or has reoccurred after failure of Chemotherapy and Immunotherapy
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborators:
Clovis Oncology, Inc.
Eli Lilly and Company
Exelixis
Treatments:
Docetaxel
Ipilimumab
Nivolumab
Ramucirumab